<DOC>
	<DOCNO>NCT02944812</DOCNO>
	<brief_summary>This trial intend : 1.To evaluate concentration Chidamide serum cerebral-spinal fluid PTCL patient certain time point take medicine , evaluate pharmacokinetics Chidamide patient CNS ( central nervous system ) distribution . 2 . To evaluate efficiency safety Chidamide PTCL patient .</brief_summary>
	<brief_title>Chidamide Refractory/Relapsed Peripheral T Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<criteria>1 . PTCL patient confirm histopathology examination . 2 . Did accept radiotherapy , chemotherapy , targetedtherapy hematopoietic stem cell transplantation within 4 week prior inclusion ; 3 . Age 1875 year old , male female ; 4 . ECOG : 01 point ; 5 . Body weight : male 67±20 kilogram ( 4787 kg ) , female 55±20 kilogram ( 3575 kg ) ; 6 . Bloodroutine test satisfy ( except lymphomarelated abnormality ) : Hb≥90g/L，ANC≥1.5×109/L，PLT≥90×109/L； 7 . Estimated survival ≥ 3 month ; 8 . Willing sign write consent trial . 1 . Women pregnancy lactation , fertile woman unwilling take contraceptive measure . 2 . QTc elongation clinical significance ( ˃ 480ms ) , ventricular tachycardia , atrial fibrillation , cardiac conducting blockage , myocardial infarction within 1 year , congestive heart failure , symptomatic coronary heart disease require treatment . 3 . Cardiac B ultrasound show enddiastolic pericardial dark zone≥ 10mm 4 . Patients receive organ transplantation . 5 . Patients receive symptomatic treatment bone marrow toxicity within 7 day prior enrollment . 6 . Patients active hemorrhage . 7 . Patients history thrombosis , embolism , cerebral hemorrhage , cerebral infarction . 8 . Patients active infection , continuous fever within 14 day prior enrollment . 9 . Had major organ surgery within 6 week prior enrollment . 10 . Impaired liver function ( Total bilirubin ˃ 1.5 time normal maximum , ALT/AST˃ 2.5 time normal maximum , patient infiltrative liver disease ALT/AST ˃ 5 time normal maximum ) , impaired renal function ( serum creatinin˃ 1.5 time normal maximum ) . 11 . Patients mental disorder ability consent ; 12 . Patients drug abuse , long term alcoholism may impact result trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>